Altimmune Inc
NASDAQ:ALT

Watchlist Manager
Altimmune Inc Logo
Altimmune Inc
NASDAQ:ALT
Watchlist
Price: 4.23 USD 15.26%
Market Cap: 325.8m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ALT stock under the Base Case scenario is 4.17 USD. Compared to the current market price of 4.23 USD, Altimmune Inc is Overvalued by 1%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALT Relative Value
Base Case
4.17 USD
Overvaluation 1%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

15 302.6
P/S
P/S
Price to Sales
15 302.6
vs History
6
vs Industry
0
Median 3Y
462.9
Median 5Y
96.7
Industry
6.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-5.4
Industry
22.3
Forward
-2.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.8
Industry
19.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.7
Industry
23.8
More Details
2.5
P/B
P/B
Price to Book Value
2.5
vs History
50
vs Industry
27
Median 3Y
2.9
Median 5Y
2.6
Industry
2.3
More Details
8 708
EV/S
EV/S
Enterprise Value to Sales
8 708
vs History
7
vs Industry
0
Median 3Y
171.6
Median 5Y
49.3
Industry
7.3
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
32
Median 3Y
-3.2
Median 5Y
-3.4
Industry
3.8
Forward
-1.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
31
Median 3Y
-3.2
Median 5Y
-3.4
Industry
3.6
Forward
-1.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
32
Median 3Y
-4.4
Median 5Y
-4.4
Industry
4.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
29
Median 3Y
-4.4
Median 5Y
-4.4
Industry
2.9
More Details
24.2
EV/IC
EV/IC
Enterprise Value to IC
24.2
vs History
31
vs Industry
6
Median 3Y
26.5
Median 5Y
9.9
Industry
4.3
More Details

Multiples Across Competitors

ALT Competitors Multiples
Altimmune Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Altimmune Inc
NASDAQ:ALT
306.1m USD 15 302.6 -3.2 -1.7 -1.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 210 447 -172 102.9 -208 987.7 -206 602.9
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.3 70.6 14.3 21.5
US
Amgen Inc
NASDAQ:AMGN
149.1B USD 4.5 36.3 15.1 26.7
US
Gilead Sciences Inc
NASDAQ:GILD
127.7B USD 4.4 265.9 10.5 13.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD 11 -226.9 24.9 26
US
Epizyme Inc
F:EPE
94.1B EUR 1 945.5 -496.5 -540.6 -526.2
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.7 26.1 16.2 20.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.6B USD 4.2 13.6 8.3 9.2
US
Seagen Inc
F:SGT
39.3B EUR 18.7 -57.5 -61.8 -55.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
29.2B USD 12.8 -103.2 -228.8 -155.5
P/S Multiple
Revenue Growth P/S to Growth
US
Altimmune Inc
NASDAQ:ALT
Average P/S: 3 293 432.8
15 302.6
1 081%
14.2
FR
Pharnext SCA
OTC:PNEXF
36 210 447
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.3
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.4
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11
10%
1.1
US
E
Epizyme Inc
F:EPE
1 945.5
N/A N/A
AU
CSL Ltd
ASX:CSL
4.7
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
7%
0.6
US
S
Seagen Inc
F:SGT
18.7
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
12.8
28%
0.5
P/E Multiple
Earnings Growth PEG
US
Altimmune Inc
NASDAQ:ALT
Average P/E: 82.5
Negative Multiple: -3.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -172 102.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
70.6
87%
0.8
US
Amgen Inc
NASDAQ:AMGN
36.3
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
265.9
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -226.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -496.5 N/A N/A
AU
CSL Ltd
ASX:CSL
26.1
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
12%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -103.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Altimmune Inc
NASDAQ:ALT
Average EV/EBITDA: 14.9
Negative Multiple: -1.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 987.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.3
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.1
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -540.6 N/A N/A
AU
CSL Ltd
ASX:CSL
16.2
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.3
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -228.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Altimmune Inc
NASDAQ:ALT
Average EV/EBIT: 19.5
Negative Multiple: -1.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -206 602.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.5
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.7
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
15%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.2 N/A N/A
AU
CSL Ltd
ASX:CSL
20.3
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.2
17%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -155.5 N/A N/A

See Also

Summary
ALT intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALT stock valuation using valuation multiples.
Wall Street Estimates
ALT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 245,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.